Amyloid-β and α-synuclein cerebrospinal fluid biomarkers andcognition in early Parkinson's disease

Parkinsonism and Related Disorders

Volumn 21, Issue 7, 2015, Pages 758-764

  Stav, Ane Løvli ^a   Aarsland, Dag ^a,b,c   Johansen, Krisztina Kunszt ^a   Hessen, Erik ^a,d   Auning, Eirik ^a,d   Fladby, Tormod ^a,d  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Alzheimer's disease; Cerebrospinal fluid biomarkers; Cognitive impairment; Parkinson's disease; Pre dementia

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; LEVODOPA; PHOSPHOPROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; LONGITUDINAL STUDY; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PEPTIDE FRAGMENTS;

EID: 84930760402     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.04.027     Document Type: Article

References (36)

1. Svenningsson P., Westman E., Ballard C., Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012, 11:697-707.
2. Adler C.H., Caviness J.N., Sabbagh M.N., Shill H.A., Connor D.J., Sue L., et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010, 120:827-828.
3. Jellinger K.A. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010, 120:829-830. author reply 31.
4. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
5. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
6. Parnetti L., Castrioto A., Chiasserini D., Persichetti E., Tambasco N., El-Agnaf O., et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 2013, 9:131-140.
7. Alves G., Bronnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J.Neurol. Neurosurg. Psychiatry 2010, 81:1080-1086.
8. Jimenez-Jimenez F.J., Alonso-Navarro H., Garcia-Martin E., Agundez J.A. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front. Cell. Neurosci. 2014, 8:369.
9. Compta Y., Marti M.J., Ibarretxe-Bilbao N., Junque C., Valldeoriola F., Munoz E., et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 2009, 24:2203-2210.
10. Yarnall A.J., Breen D.P., Duncan G.W., Khoo T.K., Coleman S.Y., Firbank M.J., et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014, 82:308-316.
11. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
12. Compta Y., Pereira J.B., Rios J., Ibarretxe-Bilbao N., Junque C., Bargallo N., et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat. Disord. 2013, 19:717-724.
13. Hall S., Surova Y., Ohrfelt A., Zetterberg H., Lindqvist D., Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015, 84:57-63.
14. Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front. Aging Neurosci. 2014, 6:53.
15. Alves G., Lange J., Blennow K., Zetterberg H., Andreasson U., Forland M.G., et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 2014, 82:1784-1790.
16. Yu S.Y., Zuo L.J., Wang F., Chen Z.J., Hu Y., Wang Y.J., et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol. 2014, 14:113.
17. Liu C., Cholerton B., Shi M., Ginghina C., Cain K.C., Auinger P., et al. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat. Disord. 2015, 21:271-276.
18. Stewart T., Liu C., Ginghina C., Cain K.C., Auinger P., Cholerton B., et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 2014, 184:966-975.
19. Buddhala C., Campbell M.C., Perlmutter J.S., Kotzbauer P.T. Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiol. Aging 2015, 36:476-484.
20. Auning E., Kjaervik V.K., Selnes P., Aarsland D., Haram A., Bjornerud A., et al. White matter integrity and cognition in Parkinson's disease: a cross-sectional study. BMJ Open 2014, 4. e003976.
21. Berardelli A., Wenning G.K., Antonini A., Berg D., Bloem B.R., Bonifati V., et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur. J. Neurol. 2013, 20:16-34.
22. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
23. Stenset V., Bjornerud A., Fjell A.M., Walhovd K.B., Hofoss D., Due-Tonnessen P., et al. Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment. Neurobiol. Aging 2011, 32:581-589.
24. Schmidt M. Rey auditory and verbal learning test. A handbook 1996, Western Psychological Services, Los Angeles, CA.
25. Heaton R.K., Taylor M.J., Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan battery: demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults 2004, Psychological Assessment Resources.
26. Lezak M.H.D., Bigler E., Tranel D. Neuropsychological Assessment - Fifth Edition 2012, Oxford University Press, Oxford.
27. Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013, 70:1277-1287.
28. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 2010, 25:2682-2685.
29. Compta Y., Ibarretxe-Bilbao N., Pereira J.B., Junque C., Bargallo N., Tolosa E., et al. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat. Disord. 2012, 18:941-947.
30. Pellecchia M.T., Picillo M., Santangelo G., Longo K., Moccia M., Erro R., et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. Acta Neurol. Scand. 2015, 131:275-281.
31. Leverenz J.B., Watson G.S., Shofer J., Zabetian C.P., Zhang J., Montine T.J. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:61-64.
32. Korff A., Liu C., Ginghina C., Shi M., Zhang J. Alzheimer's disease neuroimaging I. alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J.Alzheimers Dis. 2013, 36:679-688.
33. Slaets S., Vanmechelen E., Le Bastard N., Decraemer H., Vandijck M., Martin J.J., et al. Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement. 2014, 10:S290-S298.
34. Compta Y., Valente T., Saura J., Segura B., Iranzo A., Serradell M., et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J.Neurol. 2015, 262:294-306.
35. Qiao L., Hamamichi S., Caldwell K.A., Caldwell G.A., Yacoubian T.A., Wilson S., et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain 2008, 1:17.
36. Saido T., Leissring M.A. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb. Perspect. Med. 2012, 2. a006379.